MedKoo Cat#: 565629 | Name: UAMC-1110
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

UAMC-1110, also known as SP-13786, is a novel potent and selective inhibitor of fibroblast activation protein (fap), displaying low nanomolar inhibitory potency and high selectivity against the related dipeptidyl peptidases (dpps) dppiv, dpp9, dppii, and prolyl oligopeptidase (prep)

Chemical Structure

UAMC-1110
UAMC-1110
CAS#1448440-52-5

Theoretical Analysis

MedKoo Cat#: 565629

Name: UAMC-1110

CAS#: 1448440-52-5

Chemical Formula: C17H14F2N4O2

Exact Mass: 344.1085

Molecular Weight: 344.32

Elemental Analysis: C, 59.30; H, 4.10; F, 11.04; N, 16.27; O, 9.29

Price and Availability

Size Price Availability Quantity
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 750.00 Ready to ship
200mg USD 1,250.00 Ready to ship
500mg USD 2,650.00 Ready to ship
1g USD 3,650.00 Ready to ship
2g USD 6,250.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
Synonym
UAMC-1110; UAMC 1110; UAMC1110; SP-13786; SP 13786; SP13786;
IUPAC/Chemical Name
(S)-N-(2-(2-Cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)quinoline-4-carboxamide
InChi Key
PUOOCZVRHBHJRS-NSHDSACASA-N
InChi Code
InChI=1S/C17H14F2N4O2/c18-17(19)7-11(8-20)23(10-17)15(24)9-22-16(25)13-5-6-21-14-4-2-1-3-12(13)14/h1-6,11H,7,9-10H2,(H,22,25)/t11-/m0/s1
SMILES Code
O=C(C1=CC=NC2=CC=CC=C12)NCC(N3[C@H](C#N)CC(F)(F)C3)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
Novel potent and selective inhibitor of fibroblast activation protein (FAP).
In vitro activity:
The synthesis, biochemical characterization, and application of three different activity-based probes (biotin-, Cy3-, and Cy5-labeled) were described based on the FAP-inhibitor UAMC1110, an in-house developed molecule considered to be the most potent and selective FAP inhibitor available. The three probes have subnanomolar FAP affinity and pronounced selectivity with respect to the related S9 family members were demonstrated. Furthermore, the fluorescent Cy3- and Cy5-labeled probes were reported to be capable of selectively detecting FAP in a cellular context, making these chemical probes highly suitable for further biological studies. Moreover, proof of concept is provided for in situ FAP activity staining in patient-derived cryosections of urothelial tumors. Ref: Van Rymenant Y, Tanc M, Van Elzen R, Bracke A, De Wever O, Augustyns K, Lambeir AM, Kockx M, De Meester I, Van Der Veken P. In Vitro and In Situ Activity-Based Labeling of Fibroblast Activation Protein with UAMC1110-Derived Probes. Front Chem. 2021 Apr 14;9:640566. doi: 10.3389/fchem.2021.640566. PMID: 33996747; PMCID: PMC8114891.
In vivo activity:
TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 344.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Van Rymenant Y, Tanc M, Van Elzen R, Bracke A, De Wever O, Augustyns K, Lambeir AM, Kockx M, De Meester I, Van Der Veken P. In Vitro and In Situ Activity-Based Labeling of Fibroblast Activation Protein with UAMC1110-Derived Probes. Front Chem. 2021 Apr 14;9:640566. doi: 10.3389/fchem.2021.640566. PMID: 33996747; PMCID: PMC8114891.
In vitro protocol:
Van Rymenant Y, Tanc M, Van Elzen R, Bracke A, De Wever O, Augustyns K, Lambeir AM, Kockx M, De Meester I, Van Der Veken P. In Vitro and In Situ Activity-Based Labeling of Fibroblast Activation Protein with UAMC1110-Derived Probes. Front Chem. 2021 Apr 14;9:640566. doi: 10.3389/fchem.2021.640566. PMID: 33996747; PMCID: PMC8114891.
In vivo protocol:
TBD
1: De Decker A, Vliegen G, Van Rompaey D, Peeraer A, Bracke A, Verckist L, Jansen K, Geiss-Friedlander R, Augustyns K, De Winter H, De Meester I, Lambeir AM, Van der Veken P. Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP). ACS Med Chem Lett. 2019 Jul 9;10(8):1173-1179. doi: 10.1021/acsmedchemlett.9b00191. PMID: 31413802; PMCID: PMC6691567. 2: Moon ES, Elvas F, Vliegen G, De Lombaerde S, Vangestel C, De Bruycker S, Bracke A, Eppard E, Greifenstein L, Klasen B, Kramer V, Staelens S, De Meester I, Van der Veken P, Rösch F. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators. EJNMMI Radiopharm Chem. 2020 Jul 29;5(1):19. doi: 10.1186/s41181-020-00102-z. PMID: 32728930; PMCID: PMC7391456. 3: Gunderson AJ, Yamazaki T, McCarty K, Phillips M, Alice A, Bambina S, Zebertavage L, Friedman D, Cottam B, Newell P, Gough MJ, Crittenden MR, Van der Veken P, Young KH. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma. PLoS One. 2019 Feb 6;14(2):e0211117. doi: 10.1371/journal.pone.0211117. PMID: 30726287; PMCID: PMC6364920.